BioNTech Projects Greater Revenue Drop for 2025 Than Anticipated
FRANKFURT (Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion) and 2.2 billion euros, prompting a decline in its share price.
The guidance compares with revenues of 2.75 billion euros reported for last year and with an average analyst estimate of about 2.5 billion for 2025, according to LSEG data.
The biotech firm's German traded stock was down 4.1% at 1110 GMT.
($1 = 0.9213 euros)
(Reporting by Ludwig Burger, editing by Thomas Seythal)






